{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T23:27:59Z","timestamp":1790897279349,"version":"4.1.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,5,26]],"date-time":"2023-05-26T00:00:00Z","timestamp":1685059200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,5,26]],"date-time":"2023-05-26T00:00:00Z","timestamp":1685059200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100004386","name":"Universiti Malaya","doi-asserted-by":"publisher","award":["RG536-13HTM"],"award-info":[{"award-number":["RG536-13HTM"]}],"id":[{"id":"10.13039\/501100004386","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004386","name":"Universiti Malaya","doi-asserted-by":"publisher","award":["BKS067-2017"],"award-info":[{"award-number":["BKS067-2017"]}],"id":[{"id":"10.13039\/501100004386","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hepatol Int"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1007\/s12072-023-10550-9","type":"journal-article","created":{"date-parts":[[2023,5,26]],"date-time":"2023-05-26T17:01:54Z","timestamp":1685120514000},"page":"870-881","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Long-term clinical outcomes of adults with metabolic dysfunction-associated fatty liver disease: a single-centre prospective cohort study with baseline liver biopsy"],"prefix":"10.1007","volume":"17","author":[{"given":"Wah-Loong","family":"Chan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi-En","family":"Chong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felicia","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee-Lee","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kee-Huat","family":"Chuah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nik Raihan","family":"Nik Mustapha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjiv","family":"Mahadeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9105-5837","authenticated-orcid":false,"given":"Wah-Kheong","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,26]]},"reference":[{"issue":"12","key":"10550_CR1","doi-asserted-by":"publisher","first-page":"2809","DOI":"10.1016\/j.cgh.2021.12.002","volume":"20","author":"MH Le","year":"2022","unstructured":"Le MH, et al. 2019 Global NAFLD prevalence: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2022;20(12):2809-2817.e28","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"10550_CR2","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/S2468-1253(19)30039-1","volume":"4","author":"J Li","year":"2019","unstructured":"Li J, et al. Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999\u20132019: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2019;4(5):389\u2013398","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"4","key":"10550_CR3","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1002\/hep.28390","volume":"63","author":"A Unalp-Arida","year":"2016","unstructured":"Unalp-Arida A, Ruhl CE. Noninvasive fatty liver markers predict liver disease mortality in the U.S. population. Hepatology. 2016;63(4):1170\u20131183","journal-title":"Hepatology"},{"issue":"5","key":"10550_CR4","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1002\/hep.29085","volume":"65","author":"PS Dulai","year":"2017","unstructured":"Dulai PS, et al. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis. Hepatology. 2017;65(5):1557\u20131565","journal-title":"Hepatology"},{"issue":"2","key":"10550_CR5","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1053\/j.gastro.2015.04.043","volume":"149","author":"P Angulo","year":"2015","unstructured":"Angulo P, et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology. 2015;149(2):389-397.e10","journal-title":"Gastroenterology"},{"issue":"6","key":"10550_CR6","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1053\/j.gastro.2020.01.043","volume":"158","author":"RS Taylor","year":"2020","unstructured":"Taylor RS, et al. Association between fibrosis stage and outcomes of patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis. Gastroenterology. 2020;158(6):1611-1625.e12","journal-title":"Gastroenterology"},{"issue":"5","key":"10550_CR7","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1002\/hep.27368","volume":"61","author":"M Ekstedt","year":"2015","unstructured":"Ekstedt M, et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology. 2015;61(5):1547\u20131554","journal-title":"Hepatology"},{"issue":"1","key":"10550_CR8","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","volume":"73","author":"M Eslam","year":"2020","unstructured":"Eslam M, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020;73(1):202\u2013209","journal-title":"J Hepatol"},{"issue":"7","key":"10550_CR9","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1053\/j.gastro.2019.11.312","volume":"158","author":"M Eslam","year":"2020","unstructured":"Eslam M, Sanyal AJ, George J. MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology. 2020;158(7):1999-2014.e1","journal-title":"Gastroenterology"},{"issue":"5","key":"10550_CR10","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1016\/j.cgh.2021.01.017","volume":"19","author":"V Wai-Sun Wong","year":"2021","unstructured":"Wai-Sun Wong V, Kanwal F. On the proposed definition of metabolic-associated fatty liver disease. Clin Gastroenterol Hepatol. 2021;19(5):865\u2013870","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"10550_CR11","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1111\/liv.15142","volume":"42","author":"WK Chan","year":"2022","unstructured":"Chan WK, Wong VW. Meaning of non-overlapping patients between the MAFLD and NAFLD definitions. Liver Int. 2022;42(2):271\u2013273","journal-title":"Liver Int"},{"issue":"6","key":"10550_CR12","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1007\/s12072-020-10094-2","volume":"14","author":"M Eslam","year":"2020","unstructured":"Eslam M, et al. The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. Hepatol Int. 2020;14(6):889\u2013919","journal-title":"Hepatol Int"},{"issue":"3","key":"10550_CR13","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/S2468-1253(21)00002-9","volume":"6","author":"SS Tan","year":"2021","unstructured":"Tan SS, et al. Endorsing the redefinition of fatty liver disease. Lancet Gastroenterol Hepatol. 2021;6(3):163","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"5","key":"10550_CR14","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1111\/jgh.15787","volume":"37","author":"WK Chan","year":"2022","unstructured":"Chan WK, et al. Malaysian Society of Gastroenterology and Hepatology consensus statement on metabolic dysfunction-associated fatty liver disease. J Gastroenterol Hepatol. 2022;37(5):795\u2013811","journal-title":"J Gastroenterol Hepatol"},{"issue":"Suppl","key":"10550_CR15","doi-asserted-by":"publisher","first-page":"S58","DOI":"10.3350\/cmh.2022.0350","volume":"29","author":"WK Chan","year":"2023","unstructured":"Chan W.K. Comparison between obese and non-obese NAFLD. Clin Mol Hepatol. 2023;29(Suppl):S58\u2013S67","journal-title":"Clin Mol Hepatol"},{"issue":"1","key":"10550_CR16","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1111\/jgh.13857","volume":"33","author":"VW Wong","year":"2018","unstructured":"Wong VW, et al. Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017-Part 1: Definition, risk factors and assessment. J Gastroenterol Hepatol. 2018;33(1):70\u201385","journal-title":"J Gastroenterol Hepatol"},{"issue":"4","key":"10550_CR17","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1016\/j.jhep.2021.06.013","volume":"75","author":"X Chen","year":"2021","unstructured":"Chen X, et al. Are the different MAFLD subtypes based on the inclusion criteria correlated with all-cause mortality? J Hepatol. 2021;75(4):987\u2013989","journal-title":"J Hepatol"},{"key":"10550_CR18","doi-asserted-by":"publisher","first-page":"491","DOI":"10.2147\/RMHP.S285880","volume":"14","author":"J Huang","year":"2021","unstructured":"Huang J, et al. MAFLD criteria guide the subtyping of patients with fatty liver disease. Risk Manag Healthc Policy. 2021;14:491\u2013501","journal-title":"Risk Manag Healthc Policy"},{"issue":"6","key":"10550_CR19","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1539\/joh.45.335","volume":"45","author":"E Anuurad","year":"2003","unstructured":"Anuurad E, et al. The new BMI criteria for asians by the regional office for the western pacific region of WHO are suitable for screening of overweight to prevent metabolic syndrome in elder Japanese workers. J Occup Health. 2003;45(6):335\u2013343","journal-title":"J Occup Health"},{"issue":"9491","key":"10550_CR20","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1016\/S0140-6736(05)67402-8","volume":"366","author":"KG Alberti","year":"2005","unstructured":"Alberti KG, Zimmet P, Shaw J. The metabolic syndrome\u2013a new worldwide definition. Lancet. 2005;366(9491):1059\u20131062","journal-title":"Lancet"},{"key":"10550_CR21","unstructured":"MEMS. Clinical practice guidelines on management of type 2 diabetes mellitus. 6th ed. https:\/\/mems.my\/cpg-management-of-type-2-diabetes-mellitus-6th-edition\/ (2020). Accessed 16 Sept 2022"},{"issue":"6","key":"10550_CR22","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1161\/HYPERTENSIONAHA.120.15026","volume":"75","author":"T Unger","year":"2020","unstructured":"Unger T, et al. 2020 International society of hypertension global hypertension practice guidelines. Hypertension. 2020;75(6):1334\u20131357","journal-title":"Hypertension"},{"key":"10550_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2021.154911","volume":"126","author":"EX Tan","year":"2022","unstructured":"Tan EX, et al. Non-obese non-alcoholic fatty liver disease (NAFLD) in Asia: an international registry study. Metabolism. 2022;126: 154911","journal-title":"Metabolism"},{"issue":"6","key":"10550_CR24","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1002\/hep.20701","volume":"41","author":"DE Kleiner","year":"2005","unstructured":"Kleiner DE, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41(6):1313\u20131321","journal-title":"Hepatology"},{"issue":"4","key":"10550_CR25","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/S2468-1253(19)30383-8","volume":"5","author":"PN Newsome","year":"2020","unstructured":"Newsome PN, et al. FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study. Lancet Gastroenterol Hepatol. 2020;5(4):362\u2013373","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"17","key":"10550_CR26","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1056\/NEJMoa2029349","volume":"385","author":"AJ Sanyal","year":"2021","unstructured":"Sanyal AJ, et al. Prospective study of outcomes in adults with nonalcoholic fatty liver disease. N Engl J Med. 2021;385(17):1559\u20131569","journal-title":"N Engl J Med"},{"key":"10550_CR27","first-page":"2020","volume-title":"Non-communicable diseases, healthcare demand, and health literacy\u2014key findings","author":"National Health and Morbidity Survey (NHMS)","year":"2019","unstructured":"National Health and Morbidity Survey (NHMS). Non-communicable diseases, healthcare demand, and health literacy\u2014key findings. Putrajaya: Institute for Public Health, Ministry of Health Malaysia; 2019. p. 2020"},{"issue":"2","key":"10550_CR28","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1007\/s12072-012-9359-2","volume":"7","author":"SC Goh","year":"2013","unstructured":"Goh SC, Ho EL, Goh KL. Prevalence and risk factors of non-alcoholic fatty liver disease in a multiracial suburban Asian population in Malaysia. Hepatol Int. 2013;7(2):548\u2013554","journal-title":"Hepatol Int"},{"issue":"2","key":"10550_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.pbj.0000000000000031","volume":"4","author":"ASA Khammas","year":"2019","unstructured":"Khammas ASA, et al. Prevalence and risk factors of sonographically detected non alcoholic fatty liver disease in a screening centre in Klang Valley, Malaysia: an observational cross-sectional study. Porto Biomed J. 2019;4(2): e31","journal-title":"Porto Biomed J"},{"issue":"9","key":"10550_CR30","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.1111\/jgh.15905","volume":"37","author":"SZ Lim","year":"2022","unstructured":"Lim SZ, et al. Epidemiological trends of gastrointestinal and liver diseases in Malaysia: a single-center observational study. J Gastroenterol Hepatol. 2022;37(9):1732\u20131740","journal-title":"J Gastroenterol Hepatol"},{"issue":"3","key":"10550_CR31","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1111\/1751-2980.12223","volume":"16","author":"KL Goh","year":"2015","unstructured":"Goh KL, et al. Liver cancer in Malaysia: epidemiology and clinical presentation in a multiracial Asian population. J Dig Dis. 2015;16(3):152\u2013158","journal-title":"J Dig Dis"},{"issue":"2","key":"10550_CR32","first-page":"199","volume":"76","author":"SR Karuthan","year":"2021","unstructured":"Karuthan SR, et al. Barcelona Clinic Liver Cancer and Hong Kong Liver Cancer staging systems for prediction of survival among Hepatocellular Carcinoma patients. Med J Malaysia. 2021;76(2):199\u2013204","journal-title":"Med J Malaysia"},{"issue":"3","key":"10550_CR33","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1053\/j.gastro.2014.11.039","volume":"148","author":"RJ Wong","year":"2015","unstructured":"Wong RJ, et al. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. Gastroenterology. 2015;148(3):547\u2013555","journal-title":"Gastroenterology"},{"issue":"6","key":"10550_CR34","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1002\/hep.26986","volume":"59","author":"RJ Wong","year":"2014","unstructured":"Wong RJ, Cheung R, Ahmed A. Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the U.S. Hepatology. 2014;59(6):2188\u20132195","journal-title":"Hepatology"},{"issue":"4","key":"10550_CR35","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/j.jhep.2018.05.036","volume":"69","author":"C Estes","year":"2018","unstructured":"Estes C, et al. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016\u20132030. J Hepatol. 2018;69(4):896\u2013904","journal-title":"J Hepatol"},{"issue":"8","key":"10550_CR36","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1111\/apt.15673","volume":"51","author":"C Estes","year":"2020","unstructured":"Estes C, et al. Modelling NAFLD disease burden in four Asian regions-2019-2030. Aliment Pharmacol Ther. 2020;51(8):801\u2013811","journal-title":"Aliment Pharmacol Ther"},{"issue":"9","key":"10550_CR37","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1136\/gutjnl-2020-320622","volume":"69","author":"G Targher","year":"2020","unstructured":"Targher G, Byrne CD, Tilg H. NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications. Gut. 2020;69(9):1691\u20131705","journal-title":"Gut"},{"issue":"1","key":"10550_CR38","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1053\/j.gastro.2005.04.014","volume":"129","author":"LA Adams","year":"2005","unstructured":"Adams LA, et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology. 2005;129(1):113\u2013121","journal-title":"Gastroenterology"},{"issue":"11","key":"10550_CR39","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.3390\/healthcare9111518","volume":"9","author":"L Zhu","year":"2021","unstructured":"Zhu L, et al. Lean yet unhealthy: Asian American adults had higher risks for metabolic syndrome than Non-Hispanic White adults with the same body mass index: evidence from NHANES 2011\u20132016. Healthcare (Basel). 2021;9(11):1518","journal-title":"Healthcare (Basel)"},{"issue":"2","key":"10550_CR40","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1111\/jgh.14794","volume":"35","author":"S Khoo","year":"2020","unstructured":"Khoo S, et al. Suboptimal treatment of dyslipidemia in patients with nonalcoholic fatty liver disease. J Gastroenterol Hepatol. 2020;35(2):320\u2013325","journal-title":"J Gastroenterol Hepatol"},{"key":"10550_CR41","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.13796","author":"YW Leow","year":"2023","unstructured":"Leow YW, et al. Hepatic steatosis and metabolic risk factors among patients with chronic hepatitis B: The multicentre, prospective CAP-Asia study. J Viral Hepat. 2023. https:\/\/doi.org\/10.1111\/jvh.13796","journal-title":"J Viral Hepat"},{"issue":"2","key":"10550_CR42","doi-asserted-by":"publisher","first-page":"135","DOI":"10.21037\/hbsn.2017.03.06","volume":"6","author":"SY Loo","year":"2017","unstructured":"Loo SY, Chan WK. Emerging new standard for non-invasive assessment of liver disease mortality in non-alcoholic fatty liver disease. Hepatobiliary Surg Nutr. 2017;6(2):135\u2013137","journal-title":"Hepatobiliary Surg Nutr"},{"issue":"4","key":"10550_CR43","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1007\/s12072-014-9596-7","volume":"9","author":"WK Chan","year":"2015","unstructured":"Chan WK, Nik Mustapha NR, Mahadeva S. A novel 2-step approach combining the NAFLD fibrosis score and liver stiffness measurement for predicting advanced fibrosis. Hepatol Int. 2015;9(4):594\u2013602","journal-title":"Hepatol Int"},{"issue":"12","key":"10550_CR44","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1016\/j.cgh.2019.03.006","volume":"17","author":"WK Chan","year":"2019","unstructured":"Chan WK, et al. Optimizing use of nonalcoholic fatty liver disease fibrosis score, fibrosis-4 score, and liver stiffness measurement to identify patients with advanced fibrosis. Clin Gastroenterol Hepatol. 2019;17(12):2570-2580.e37","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"10550_CR45","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1111\/liv.15139","volume":"42","author":"I Ayada","year":"2022","unstructured":"Ayada I, et al. Systematically comparing epidemiological and clinical features of MAFLD and NAFLD by meta-analysis: focusing on the non-overlap groups. Liver Int. 2022;42(2):277\u2013287","journal-title":"Liver Int"},{"issue":"5","key":"10550_CR46","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1002\/hep.32499","volume":"76","author":"ZM Younossi","year":"2022","unstructured":"Younossi ZM, et al. Are there outcome differences between NAFLD and metabolic-associated fatty liver disease? Hepatology. 2022;76(5):1423\u20131437","journal-title":"Hepatology"},{"issue":"2","key":"10550_CR47","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1002\/hep.32131","volume":"75","author":"LA van Kleef","year":"2022","unstructured":"van Kleef LA, et al. Metabolic dysfunction-associated fatty liver disease improves detection of high liver stiffness: The Rotterdam Study. Hepatology. 2022;75(2):419\u2013429","journal-title":"Hepatology"}],"container-title":["Hepatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-023-10550-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12072-023-10550-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-023-10550-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T00:45:18Z","timestamp":1744159518000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12072-023-10550-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,26]]},"references-count":47,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["10550"],"URL":"https:\/\/doi.org\/10.1007\/s12072-023-10550-9","relation":{},"ISSN":["1936-0533","1936-0541"],"issn-type":[{"value":"1936-0533","type":"print"},{"value":"1936-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,26]]},"assertion":[{"value":"5 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"WKC has served as a consultant or advisory board member for Roche, Abbvie, Boehringer Ingelheim and Novo Nordisk; and a speaker for Viatris and Hisky Medical. The other authors have no conflict of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This is a single-centre prospective study of a well-characterized cohort of NAFLD patients. The study followed the ethical guidelines of the 1975 Helsinki Declaration, and ethical approval was obtained from our institutional review board prior to the commencement of the study (MECID. No.: 20168124134).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All participating subjects provided informed consent.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}